BACKGROUND: It is suspected that there is a continuum of impairment among prenatally drug-exposed infants, such that opioid and/or poly-drug exposure confers the highest risk for adverse neonatal outcomes than other classes of substances or single substance exposures. Suitable control groups are difficult to identify. This study compared fetal neurobehavioral development and infant outcomes in offspring of three groups of pregnant women in drug treatment. Exposure groups include: Methadone+other illicit substances (MM+Poly) and two groups currently abstinent for poly drug exposures: Methadone only (MM/A) and Non-Methadone (NM/A). METHODS: Forty-nine women (19 MM+Poly, 18 MM/A, and 12 NM/A) underwent fetal monitoring at 36 weeks gestation at peak and trough levels of methadone (MM+Poly; MM/A) or at comparable morning and afternoon times (NM/A). Fetal heart rate (FHR), heart rate variability (FHRV) and motor activity (FM) data were collected. Infant measures included birth outcomes and Neonatal Abstinence Syndrome (NAS) assessment. RESULTS: As compared to the NM/A group, cardiac measures were decreased in methadone-exposed fetuses at peak levels. FHR was significantly more suppressed in the MM+Poly group. FM was significantly lower in the MM/A vs. the NM/A group at both peak and trough, indicative of more persistent exposure effects. The MM+Poly group delivered 1 week earlier and required NAS pharmacological treatment twice as often as the MM/A group. CONCLUSIONS: Results support the notion that poly-drug exposure may potentiate the effects of methadone on the fetus and infant and highlights the need for intensified treatment for methadone-maintained women who abuse other substances.
BACKGROUND: It is suspected that there is a continuum of impairment among prenatally drug-exposed infants, such that opioid and/or poly-drug exposure confers the highest risk for adverse neonatal outcomes than other classes of substances or single substance exposures. Suitable control groups are difficult to identify. This study compared fetal neurobehavioral development and infant outcomes in offspring of three groups of pregnant women in drug treatment. Exposure groups include: Methadone+other illicit substances (MM+Poly) and two groups currently abstinent for poly drug exposures: Methadone only (MM/A) and Non-Methadone (NM/A). METHODS: Forty-nine women (19 MM+Poly, 18 MM/A, and 12 NM/A) underwent fetal monitoring at 36 weeks gestation at peak and trough levels of methadone (MM+Poly; MM/A) or at comparable morning and afternoon times (NM/A). Fetal heart rate (FHR), heart rate variability (FHRV) and motor activity (FM) data were collected. Infant measures included birth outcomes and Neonatal Abstinence Syndrome (NAS) assessment. RESULTS: As compared to the NM/A group, cardiac measures were decreased in methadone-exposed fetuses at peak levels. FHR was significantly more suppressed in the MM+Poly group. FM was significantly lower in the MM/A vs. the NM/A group at both peak and trough, indicative of more persistent exposure effects. The MM+Poly group delivered 1 week earlier and required NAS pharmacological treatment twice as often as the MM/A group. CONCLUSIONS: Results support the notion that poly-drug exposure may potentiate the effects of methadone on the fetus and infant and highlights the need for intensified treatment for methadone-maintained women who abuse other substances.
Authors: Laura R Stroud; Rachel L Paster; George D Papandonatos; Raymond Niaura; Amy L Salisbury; Cynthia Battle; Linda L Lagasse; Barry Lester Journal: J Pediatr Date: 2008-11-05 Impact factor: 4.406
Authors: Lauren M Jansson; Janet A Dipietro; Martha Velez; Andrea Elko; Heather Knauer; Katie T Kivlighan Journal: J Matern Fetal Neonatal Med Date: 2009-01
Authors: J Rampono; K Simmer; K F Ilett; L P Hackett; D A Doherty; R Elliot; C H Kok; A Coenen; T Forman Journal: Pharmacopsychiatry Date: 2009-05-18 Impact factor: 5.788
Authors: Brittany L Smith; Eric S Hall; Jennifer M McAllister; Michael P Marcotte; Kenneth D R Setchell; Vandana Megaraj; Kristine L Jimenez; T John Winhusen; Scott L Wexelblatt Journal: J Perinatol Date: 2022-02-17 Impact factor: 3.225
Authors: Janet A DiPietro; Meghan F Davis; Kathleen A Costigan; Dana Boyd Barr Journal: J Expo Sci Environ Epidemiol Date: 2013-04-17 Impact factor: 5.563
Authors: Laura Garrison; Lawrence Leeman; Renate D Savich; Hilda Gutierrez; William F Rayburn; Ludmila N Bakhireva Journal: J Reprod Med Date: 2016 Jul-Aug Impact factor: 0.142